In Japan, four classes and five kinds of disease-modifying drugs (DMD), such as interferon-beta (IFNb1a and IFNb1b), glatiramer acetate, fingolimod and natalizumab, are approved as curative treatments for multiple sclerosis. There are advantages and disadvantages of each of these DMD, and treatment guidelines for escalation and induction therapy have yet to be established. Escalation therapy starts with a first-line DMD, and when the first-line DMD does not provide optimal efficacy, therapy involves a step-up to a second DMD. Induction therapy supports the early use of a highly effective second DMD for the purpose of long-term maintenance treatment. The DMD can be separated by their treatment efficacy and long-term safety. Because of their demonstrated long-term safety and efficacy, the drugs of choice are first-line DMD (IFNb and glatiramer acetate). In addition, their long-term administration has not been associated with malignancies, opportunistic infections, secondary immune disease or fetal toxicity. Though fingolimod and natalizumab have been shown to have high efficacy, their long-term safety has not been established; thus, they are used as second-line therapies. The physician sometimes has to consider switching DMD when treating multiple sclerosis patients. The reasons for changing treatment are lack of efficacy, intolerability, adverse effects, cost, pregnancy, incorrect diagnosis and disease stability. The present review provides a general introduction to the most recent findings to help practitioners determine when and how DMD treatment should be changed for multiple sclerosis.
Introduction
The clinical course of relapsing-remitting multiple sclerosis (RRMS) is characterized by a mainly inflammatory pathology that, over time, gives a largely neurodegenerative component. 1 After an average of 15-20 years, most cases of RRMS have evolved to secondary progressive MS. The window of opportunity for current disease-modifying drugs (DMD) is when inflammatory infiltrates are still being generated, which is typically from the time of a clinically isolated syndrome suggestive of MS through to early-to-mid stages of clinically definite RRMS. DMD are most effective in patients with clinically isolated syndrome or RRMS, and less effective in secondary progressive MS (Fig. 1) . 2 This time window for treatment is relatively short; therefore, timely and appropriate optimization of treatment is required in MS patients. The introduction of DMD for the management of RRMS has changed over the decades.
In the USA and EU, the currently approved DMD for MS are glatiramer acetate (GA), interferonbeta1a (IFNb1a), IFNb1b, terifulunomide, dimethyl fumarate, fingolimod, natalizumab and alemtuzumab. In Japan, GA, IFNb1a, IFNb1b, fingolimod and natalizumab are approved (Table 1) . 3 When the disease course shows a suboptimal response, escalation therapy (second-line therapy after the first-line DMD) could be used. In MS patients with high disease activity, induction therapy (starting immediately with aggressive second or third-line DMD) seems to have more relevant shortand long-lasting beneficial effects. 4, 5 In Japan, firstline DMD (IFNb and GA) are easy to use because their long-term safety and efficacy are established. In contrast, second-line DMD (fingolimod and natalizumab) have potent therapeutic effects, but their long-term safety has not yet been shown.
There are two different therapeutic approaches, escalation and induction therapy. Escalation therapy consists of starting a first-line DMD, and when the first-line DMD shows suboptimal effects, on-going therapy is switched to a second-line DMD. Induction therapy supports the early use of a highly effective second-or third-line DMD followed by long-term maintenance treatment.
There is no guideline for the treatment of MS that helps determine how and when to switch from the first-line to a second-or third-line DMD (as escalation therapy), or how induction therapy should be carried out. 3 How to carry out a therapeutic switch in MS has also not yet been determined. Thus, we have to decide the best treatment for MS patients considering each individual situation and risk profiling.
When to switch treatment?
The first reason for switching treatment is a poor response and/or poor tolerability (Table 2) . 3, 6 IFNb and GA have no or modest effects on disability progression, 7, 8 and approximately one-third of MS patients treated with IFNb are reported to be nonresponsive to treatment (having more than one relapse or a sustained Expanded Disability Status Scale (EDSS) increase of ≥0.5 points after 1 year of treatment compared with the year before therapy). [9] [10] [11] A typical poor response to first-line treatment is a patient with ongoing relapse and/or progressive disability and/or a new or enlarging lesion on magnetic resonance imaging (MRI). The most widely studied short-term factors for predicting the long-term response to IFNb are clinical relapses and MRI markers, but the results have been contradictory. A potentially useful approach that has recently been attempted is to integrate strategies combining MRI and clinical markers in scoring systems and develop an evidence-based quantitative algorithm to monitor response to IFNb, based on the Modified Rio Score for assessing the risk of progression over 4 years in MS patients treated with IFNb for 1.5 years. The definition of substantial new T2 activity was >4-5 new T2 lesions during 1 year of treatment, or, if the reference MRI scan for assessing new T2 lesion formation was obtained at least 6 months after starting therapy, >1-2 new T2 lesions. 12 Sormani et al. 13 have developed a simple, quantitative, complementary tool to predict responses in IFNb-treated patients in order to assist clinicians in their treatment decisions. As a guide for clinical decision-making, a method of predicting response to IFNb treatment has been developed based on a modified version of the original Rio scoring system. The modified Rio Score stratifies patients into four groups based on the number of new T2 lesions on MRI and the number of clinical relapses during the first year of treatment (0: new T2 lesions ≤4 and relapse 0, 1: new lesions ≤4 and relapse = 1, or new T2 lesions >4 and relapse 0, 2: new lesions ≤4 and relapses ≥2, or new T2 lesions >4 and relapses 1, 3: new T2 lesions >4 and relapses ≥2). High scores are associated with an increased risk of progressive disability over the next 4 years.
Sormani et al. 14 developed a new simplified scoring system by introducing the classification of "nonresponder'' for patients who have new T2 lesions on MRI during the first 6 months of therapy. The effect of a DMD on MRI lesions over a 6-9-month period was predictive of its effects on relapse over longer follow-up periods (12-24 months) in patients with RRMS.
Sormani et al. 15 showed that the risk of failure increased with one relapse (hazard ratio 1.84, P < 0.001) and ≥3 new T2 lesions (hazard ratio 1.55, P < 0.09). Among patients with no relapses and fewer than three new T2 lesions, the 3-year risks of failure and EDSS worsening were 17% and 15%, respectively; in those with one relapse or ≥3 new T2 lesions, the risks were 27% and 22%, respectively; among those having both conditions or more than one relapse, the risks were 48% (P < 0.001) and 29% (P < 0.001), respectively. Substantial MRI activity, particularly when combined with clinical relapses, during the first year of treatment with IFNb suggests a significant short-term risk of treatment failure and EDSS worsening. Those reports showed that the scoring of MRI activity could be used as a surrogate for relapse.
Gallo et al. recommended the following basic DMD switching principles and suggestions for use in every day clinical practice:
1. Screen for disease activity, especially during the first 2 years of treatment, and consider monitoring/surveillance with MRI; 2. Consider prognostic factors as guides for switch decisions; switch suboptimal response quickly; with a poor prognosis, consider a timely switch to a second-line DMD; accurately evaluate and document the relapse rate, EDSS increases, and MRI changes/activities; 3. Switches based on cognitive loss require formal testing for verification; 4. Avoid delaying a switch. All that can be done should be done to stop disease progression and prevent physical and cognitive impairments. Switching from one first-line DMD to another firstline DMD: Lateral switch therapy A lateral switching therapy; that is, changing treatment from low-dose/frequency to high-dose IFNb, from IFNb to GA or from GA to IFNb -is an adopted strategy in case of treatment failure or intolerability. 16 Switching treatment might help RRMS patients who show an inadequate response to first-line immunomodulatory therapy. Carr a et al. 17 showed that, in RRMS patients who fail first-line immunomodulatory therapy, switching to another class of immunomodulatory therapy is generally effective. Patients were switched either from lowdose to high-dose IFNb (n = 31), from IFNb to GA (n = 52) or mitoxantrone (n = 13), or from GA to IFNb (n = 16). Over the 3 years after switching, the annualized relapse rates decreased by 57-78% depending on the group, with an increase in the proportion of relapse-free patients from 56% to 81%. The least amount of improvement was observed in patients who were switched between IFNb preparations. The median EDSS scores did not show progression, except in those who switched from GA to IFNb.
Gajofatto et al. 18 studied the outcomes of patients who were switchers for failure, switchers not for failure or non-switchers after a suboptimal response to a first-line DMD (either IFNb or GA). Disease activity was suppressed in all treatment switchers in the switchers for failure group, but the decrease in the median annualized relapse rate was significant for IFNb/IFNb and GA/IFNb switchers, but not for IFNb/GA switchers. Disease activity was sufficiently stabilized even if the treatment was changed between IFNb1a, IFNb1b and GA.
Caon et al. 19 reported the efficacy of GA in patients who had been treated with IFNb1a. Treatment with IFNb1a reduced the mean annual relapse rate (ARR) from 1.41 to 1.23 (P = 0.005). All 85 patients treated with IFNb1a were then switched to GA as a result of persistent clinical disease activity or persistently unacceptable toxicity. Treatment with GA reduced the mean ARR from 1.23 to 0.53 (P = 0.0001). On subgroup analysis, in patients who were switched because of lack of efficacy, the mean ARR decreased from 1.32 on IFNb1a to 0.52 on GA (P = 0.0001). In contrast, the mean ARR decreased from 0.61 on IFNb1a to 0.47 on GA in patients who were switched because of persistent toxicity. In their view, clinical observations, such as relapse rate and tolerability, are appropriate as criteria for switching DMD in clinical practice.
Therefore, a therapeutic effect could be expected by switching to another first-line DMD, when a patient treated with a first-line DMD is discontinued because of a side-effect or a suboptimal effect.
Switching from IFNb or GA does not appear to require any washout period, and a new agent can be initiated as soon as feasible.
Fatigue is one of the most common and disabling MS symptoms that affects 50-75% of patients. 20, 21 GA could help reduce MS-related fatigue. Meca-Lallana et al. 22 reported that GA helps decrease MSrelated fatigue, after switching from IFNb.
Switching from first-line to second-line because of a suboptimal treatment effect
In the EU, failure of first-line DMD as a requirement for escalation therapy to fingolimod or natalizumab has been defined as ongoing high disease activity despite at least 1 year of adequate first-line therapy with a first-line DMD.
High disease activity is determined as follows:
1. The presence of at least one relapse and at least nine T2-hyperintense lesions or one contrastenhanced lesion; or 2. A relapse rate that is unchanged or higher than the year before therapy. 3 However, the above recommendation results in several questions as to how to value an increasing MRI lesion load in clinically stable patients or how to judge a patient with rare, but severe, relapses with the development of permanent disability.
The modified Rio score is an easy to use method to predict the response to DMD therapy, and it combines the incidence of new T2 lesions with the development of relapses (Table 3) . 12 The Canadian Multiple Sclerosis Working Group developed practical criteria for relapse, EDSS progression and MRI in order to create a three-tier classification of the clinical level of concern: low, medium and high. The Canadian Multiple Sclerosis Working Group recommended considering a change in treatment in any RRMS patient with: high for any one domain (relapse, progression or MRI); medium for any two domains; or low for all three domains. Table 4 shows determining the level based on relapse rate. Table 5 shows determining the level based on disability progression. Table 6 shows determining the level based on annual MRI findings. 2 
Escalation therapy
Escalation therapy to a second-line DMD would be indicated in patients with a suboptimal response to a first-line DMD or an aggressive disease course from disease onset. The second-line DMD, fingolimod and natalizumab, appear to have greater efficacy and possible adverse effects that are generally manageable. However, progressive multifocal leukoencephalopathy (PML) is associated with natalizumab 23 and fingolimod, 24, 25 and cardiovascular events are possible with fingolimod. The long-term safety and efficacy of these DMD have not been established. 2 In the phase 3 TRANSFORMS and FREEDOMS trials, fingolimod was found to be superior to a placebo and IFNb1a in regard to decreasing the relapse rate, as well as for MRI measures. 26, 27 A USA Claims Database Study evaluated MS patients switched from IFNb to fingolimod or GA. Patients who were switched from IFNb to fingolimod were found to have a 59% lower probability of relapse (odds ratio 0.41) and 62% fewer relapses per The cut-off of four lesions was in the validation set; the cut-off of five lesions was in the training set. year (rate ratio 0.38; P = 0.0013) than patients who were switched from IFNb to GA. 28 The EPOC trial compared switching to fingolimod versus remaining on any of the injectable DMD (GA or IFNb). 29 After 6 months, changes in the Treatment Satisfaction Questionnaire for Medication Global Satisfaction score, Fatigue Severity Scale score (the 10-item Fatigue Severity Scale was used to assess fatigue severity and its effects on daily living, with higher scores indicating greater fatigue severity) and Beck Depression Inventory-II (the Beck Depression Inventory-II, which contains 21 multiple-choice questions, was used to evaluate changes in patient-reported depression during the trial; higher scores indicate greater severity of depression) and 36-item ShortForm Health Survey score (the 36-item Short-Form Health Survey was used to evaluate health-related quality of life) were better after a switch to fingolimod than after remaining on any of the injectable DMD. The efficacy of fingolimod was better in na€ ıve highly active treatment than in non-IFNb responder patients. However, the European Medicines Agency has not approved fingolimod as a first-line DMD because of unforeseen long-term risks for infection and malignancy. 30 In contrast, the US Food and Drug Administration has allowed prescription of fingolimod as a first-line DMD in RRMS. Furthermore, the Canadian MS working group also placed this drug as a second-line treatment option. 31 According to the Japanese guidelines for MS, the drug should be used as a second-line option in patients showing only a suboptimal response to IFNb1a and/or IFNb1b, or in those with intolerable adverse events associated with those treatments or very high disease activity. 32 In the placebo-controlled AFFIRM study, one of the exclusion criteria was treatment with IFNb or GA within the 6 months before study entry. 31 It was found that the ARR was significantly reduced by 68% with natalizumab compared with a placebo (0.23 vs 0.73), and natalizumab reduced the risk of progression to sustained disability over 2 years by 42% (hazard ratio 0.58), decreased the mean cumulative number of T2 new/newly enlarged lesions by 85% compared with a placebo and decreased the mean number of gadolinium-enhancing lesions by 92% compared with a placebo. 31 In addition, a prospective cohort study suggested that, with active disease during treatment with injectable DMD, it was more effective to switch to natalizumab than to switch to fingolimod with respect to the relapse rate and disability burden during the first year after the switch. 33 No evidence of disease activity has been recently proposed as the principal aim in the management of RRMS, because it leads to better long-term outcomes. 34 Prosperini et al. 35 reported that natalizumab was more effective than both fingolimod and injectable DMD in non-responders. In that study, non-responder was defined as patients who experienced either two or more relapses or one relapse associated with an EDSS score ≥2.0 in the previous year on GA or IFNb. In non-responders, the 24-month proportion with no evidence of disease activity-3 (absence of relapse, disability worsening and radiological activity) was greater in both the natalizumab group (67%) and the fingolimod group (42%) than in the injectable DMD group (35%; P < 0.016), whereas in highly active treatment-na€ ıve patients, the 24-month proportion with no evidence of disease activity-3 was greater in the natalizumab group (75%) and fingolimod group (67%) than the injectable DMD group (40%). Those results suggested that natalizumab was more effective than fingolimod and injectable DMD.
It is recommended that all natalizumab candidates be tested for John Cunningham virus (JCV) antibody status before starting treatment. Patients who are antibody-positive might choose natalizumab after they are fully informed of the risk of PML, or they might prefer to start another second-line DMD, such as fingolimod. For antibody-positive patients who have been previously treated with immunosuppressants, natalizumab is generally not recommended. 36 Some patients with a low JCV index (<1.5) might continue natalizumab treatment after they have been fully informed of the risk of PML, and they must then be carefully observed for new clinical manifestations related to PML.
37,38

Induction therapy
There is evidence of axonal loss early in the course of MS. This destruction of axons, often regarded as part of a neurodegenerative process, might be even greater in the early stage of MS. 39 The main purpose of MS treatment in the relapsing phase is antiinflammation. Importantly, long-term follow up of patients with early MS treated with high-intensive DMD, such as alemutuzumab or bone marrow transplantation, reported favorable long-term outcomes. 40 Therefore, induction therapy with a high-efficacy DMD, such as natalizumab and alemtuzumab. Induction therapy is given as a short course, and can induce long-term remission and the possibility of a cure.
A post-hoc analysis determined the efficacy of natalizumab in highly active MS. That study found that natalizumab significantly reduced the risk of disability progression by 64% and the relapse rate by 81% in treatment-na€ ıve patients with highly active disease, and by 58% and 76%, respectively, in patients with highly active disease despite IFNb1a treatment. 41 Alemtuzumab is a more effective treatment than IFNb in patients with early active RRMS. This is clearly documented in the three trials. [42] [43] [44] These articles reported that with sustained accumulation of disability, the annual relapse rates were lower in the alemtuzumab groups compared with the IFNb1a groups. In contrast, the percentages of relapse-free patients were higher in the alemtuzumab groups compared with the IFNb1a groups. Considering the data of those studies, alemtuzumab might be considered a good candidate for an induction strategy in MS.
However, the safety of induction therapy has to be considered in the choice of the initial DMD; although efficacy is very important, it must be balanced by acceptable risk. High-efficacy strategies carry the risk of potentially very serious or even fatal adverse events. 45 Alemtuzumab is associated with serious autoimmune disorders. 43 Therefore, induction therapy is generally reserved for patients with very active and aggressive disease. 46 Switching from natalizumab to another DMD in patients at high risk of PML MS patients treated with natalizumab who are JCVseropositive have a high risk of PML. 37, 47 The risk of PML is particularly high in MS patients who have: (i) been treated with natalizumab for longer than 24 months; (ii) had previous exposure to immunosuppressive agents; and/or (iii) have a high anti-JCV antibody index. 37, 47 Such situations require consideration of the options for switching from natalizumab. However, MS patients treated with natalizumab had severe disease activity and an increased risk of rebound of MS disease activity occurring 3-4 months after stopping natalizumab. 48, 49 The use of methylprednisolone pulse therapy, IFNb or glatiramer acetate could not prevent the rebound associated with stopping natalizumab. 50 To prevent rebound disease activity, Giovannoni et al. 51 recommended starting a different DMD, such as fingolimod, as soon as possible, preferably within 4 weeks of the last natalizumab infusion. Several published data showed that starting fingolimod as the follow-on agent within 4 weeks of the last natalizumab infusion prevents rebound disease activity. 52, 53 However, several MS patients have developed PML on fingolimod after switching from natalizumab 54 or without prior natalizumab exposure. 25, 55 How to switch DMD for MS patients hoping to bear a child Of the DMD approved by the the US Food and Drug Administration, fetal toxicity category B, GA has the least fetal effects and is the first-line treatment for MS patients wanting to become pregnant. IFNb is the second-line treatment, though very close monitoring of MS patients treated with IFNb who want to become pregnant is required. IFNb treatment should Induction therapy Escalation therapy Figure 2 Use of disease-modifying drug for multiple sclerosis (MS) patients who hope to bear a child. GA, glatiramer acetate; IFNb, interferon-b. Adapted from Michel et al. 46 and Fabian 59 with permission.
Diagnose as MS
be stopped immediately when it has become clear that the patient is pregnant. 56 In other countries, treatment with two DMD, GA and IFNb, can be given during pregnancy, but natalizumab is possible for patients with very high disease activity; it is indicated in cases when the maternal benefits outweigh the risks. 57 Adverse fetal events have been reported in pregnant women exposed to fingolimod, and it is important to stop treatment for 2 months in the lead-up to pregnancy. However, because of the potential for recurrence when fingolimod is not used, a switch to IFNb, GA, steroid or natalizumab has been thought preferable, but standard guidelines are lacking in Japan and other countries. 58 MS treatment strategies taking into account MS patients who want to bear children are presented in Figure 2 . 46, 59 GA is the first choice, and IFNb is the second choice for such patients. However, if disease activity is high or the patient cannot continue with a first-line DMD because of side-effects, fingolimod or natalizumab can stabilize disease activity. However, fingolimod should be stopped for 2 months before attempting to achieve conception, and changed to glatiramer acetate, IFN or natalizumab in preparation for pregnancy.
Conclusion
Increasing evidence has shown that switching treatment from a first-line DMD to a second-line DMD, such as fingolimod or natalizumab, is probably more effective in RRMS. A recent study suggested that, in active disease during treatment with a first-line DMD, switching to natalizumab was more effective than switching to fingolimod. However, natalizumab and fingolimod have serious adverse events, such as PML. Furthermore, MS is increasingly a disease of women, many of whom are of childbearing age, and, therefore, the management of DMD in relation to pregnancy is important. The most important treatment strategy and approach of MS is based on the individual's disease activity and the longitudinal safety of DMD.
